GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Cash-to-Debt

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Cash-to-Debt : No Debt (1) (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bellevue Life Sciences Acquisition's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Bellevue Life Sciences Acquisition could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Bellevue Life Sciences Acquisition's Cash-to-Debt or its related term are showing as below:

BLAC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01   Med: 0.16   Max: No Debt
Current: 0.08

During the past 4 years, Bellevue Life Sciences Acquisition's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 0.16.

BLAC's Cash-to-Debt is ranked worse than
79.71% of 547 companies
in the Diversified Financial Services industry
Industry Median: 3.34 vs BLAC: 0.08

Bellevue Life Sciences Acquisition Cash-to-Debt Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Bellevue Life Sciences Acquisition Cash-to-Debt Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
0.21 0.01 0.10 No Debt

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.10 No Debt No Debt 0.29 No Debt

Competitive Comparison of Bellevue Life Sciences Acquisition's Cash-to-Debt

For the Shell Companies subindustry, Bellevue Life Sciences Acquisition's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bellevue Life Sciences Acquisition's Cash-to-Debt Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Bellevue Life Sciences Acquisition's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Bellevue Life Sciences Acquisition's Cash-to-Debt falls into.


Bellevue Life Sciences Acquisition Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Bellevue Life Sciences Acquisition's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Bellevue Life Sciences Acquisition had no debt (1).

Bellevue Life Sciences Acquisition's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Bellevue Life Sciences Acquisition had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bellevue Life Sciences Acquisition  (NAS:BLAC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Bellevue Life Sciences Acquisition Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Cash-to-Debt
Comparable Companies
ADEX NBST RWOD PMGM QDRO ONYX BOWN MSSA TBMC VII PBAJ SVMB SCRM CVII AAC GHIX ALCC AACT DWAC SAGA
Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Website
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004